Notice of Annual Report and Annual General Meeting

18 April 2012

LSE: VER

NOTICE OF ANNUAL REPORT AND ANNUAL GENERAL MEETING

Vernalis plc (LSE: VER) today gives notice of the following:

·; that copies of the Group's Annual Report and Accounts for the year ending 31 December 2011, the Notice of Annual General Meeting ("AGM") and Form of Proxy have been sent to shareholders today. These documents are also available on the Investor Centre page of the Company's web site at www.vernalis.com;

·; that its AGM will be held on Tuesday 22 May 2012 at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH at 11.00 am;

·; in accordance with Listing Rule 9.6.1, copies of relevant documents have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.hemscott.com/nsm.do;

Enquiries:

Notes to Editors

About Vernalis

Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough/cold market as well as eight programmes in its NCE development pipeline. Vernalis has significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products are endorsed by collaborations with Endo, Genentech, GSK, Lundbeck, Menarini, Novartis, Servier and Tris.

For further information about Vernalis, please visit www.vernalis.com

Vernalis Forward-Looking Statement

This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.